Form 4: Dyne Therapeutics SVP Richard Scalzo Sells Shares to Cover Tax Obligations and Under 10b5-1 Plan
SEC Form 4
Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold shares of common stock on June 10 and June 11, 2024, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.
Summary
- Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 1,590 shares of common stock on June 10, 2024, at a weighted average price of $30.23.
- These sales were executed under a Rule 10b5-1 trading plan adopted on July 11, 2023.
- On June 11, 2024, Scalzo sold 1,331 shares at a weighted average price of $31.34 to satisfy tax withholding obligations related to vesting restricted stock units.
- Following these transactions, Scalzo beneficially owns 113,774 shares, including 107,035 unvested RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing plan and to cover tax obligations, which are routine transactions.
Industry Context
Insider sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information.
Stakeholder Impact
- The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| July 11, 2023 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| December 10, 2021 | Date of restricted stock units granted to the Reporting Person |
| December 9, 2022 | Date of restricted stock units granted to the Reporting Person |
| June 10, 2024 | Date of first reported transaction (sale of 1,590 shares) |
| June 11, 2024 | Date of second reported transaction (sale of 1,331 shares) |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.